To assess whether postexposure protection of ECs against EBOV infection can be conferred by pharmacological inactivation of EPAC1, HUVECs were treated with ESI09 and NY0123 at 24 h after infection with EBOV at an MOI of 0.5. This evidence concerns the gene RAPGEF3 and infection.